Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic - 2Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- 3Kuwait is softening stance on Israel, dissident tells ‘Post’ after viral UN speech
- 4Giude to Best Web based Learning Stage
- 5German foreign minister heads to China to talk rare-earth exports
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
- Top 15 Web-based Entertainment Stages for Individual Marking
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
- ‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
- Horses really can smell our fear, new study finds
- Find the Captivating Professional flowerbeds of the US
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- What to know about King Charles III's cancer treatment and his message to the public
